CIBC Asset Management
PBYI icon

CIBC Asset Management’s Puma Biotechnology PBYI Stock Holding History

CIBC Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-877
Closed -$207K – 994
2015
Q1 		$207K Buy
+877
New +$187K ﹤0.01% 898
2014
Q4 		– Sell
-920
Closed -$219K – 968
2014
Q3 		$219K Buy
+920
New +$189K ﹤0.01% 878

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

CIBC Asset Management's PBYI Position: Q2 2015 in Review

CIBC Asset Management sold out of Puma Biotechnology (PBYI) in Q2 2015, closing a stake of 877 shares — an estimated $207K sold.

CIBC Asset Management first reported a position in PBYI in Q3 2014 and held it in 2 quarters. The position peaked at $219K in Q3 2014. 198 funds tracked by Wall St. Rank hold PBYI as of Q2 2015.

  • CIBC Asset Management reported no remaining Puma Biotechnology position as of Q2 2015 after selling out during the quarter.
  • CIBC Asset Management sold 877 Puma Biotechnology shares in Q2 2015, an estimated $207K.
  • CIBC Asset Management first reported a position in Puma Biotechnology in Q3 2014 and held it in 2 quarters.
  • CIBC Asset Management's Puma Biotechnology position peaked at $219K in Q3 2014.
  • 198 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2015.

Based on CIBC Asset Management's 13F filing for Q2 2015, filed 6 Aug 2015.